Usefulness of initial plasma dabigatran concentration to predict rebound after reversal

• Nicolas Gendron,
• Juliette Gay,
• Marine Lemoine,
• Pascale Gaussem,
• Agnès Lillo-Le-Louet,
• David M. Smadja

Affiliations

Nicolas Gendron

AP-HP, European Hospital Georges Pompidou, Hematology Department, Paris, France;Université Paris Descartes, Sorbonne Paris Cite, Paris, France;Inserm UMR-S1140, Paris, France

Juliette Gay

AP-HP, European Hospital Georges Pompidou, Hematology Department, Paris, France;Université Paris Descartes, Sorbonne Paris Cite, Paris, France

Marine Lemoine

AP-HP, European Hospital Georges Pompidou, Regional Center of Pharmacovigilance, Paris, France

Pascale Gaussem

AP-HP, European Hospital Georges Pompidou, Hematology Department, Paris, France;Université Paris Descartes, Sorbonne Paris Cite, Paris, France;Inserm UMR-S1140, Paris, France

Agnès Lillo-Le-Louet

AP-HP, European Hospital Georges Pompidou, Regional Center of Pharmacovigilance, Paris, France

David M. Smadja

AP-HP, European Hospital Georges Pompidou, Hematology Department, Paris, France;Université Paris Descartes, Sorbonne Paris Cite, Paris, France;Inserm UMR-S1140, Paris, France